Pfizer Inc. and the European Foundation for the Study of Diabetes Announce a New Research Program Focused on Cardiovascular Risk in Patients with Diabetes

AMSTERDAM, Netherlands--(BUSINESS WIRE)--Pfizer and the European Foundation for the Study of Diabetes (EFSD) announced today, at the European Association for the Study of Diabetes (EASD) Annual Meeting, the development of a new awards program which will provide research grants to support European research around understanding and reducing cardiovascular risk in patients with diabetes.
MORE ON THIS TOPIC